This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saksena, S. Articles by Camm, A. J. Search for Related Content PubMed PubMed Citation Articles by Saksena, S. Articles by Camm, A. J.

Circulation, Vol 85, 2316-2321, Copyright © 1992 by American Heart Association

ARTICLES

Implantable defibrillators for prevention of sudden death. Technology at a medical and economic crossroad

S Saksena and AJ Camm

Implantable cardioverter-defibrillator therapy is now widely used for the treatment of symptomatic patients with documented or suspected life- threatening VTs. Although sudden death recurrence in ICD recipients is virtually eliminated, the extent of benefit both with respect to cardiac mortality and total survival in this patient population remains to be accurately quantitated, particularly vis-a-vis alternative antiarrhythmic therapies. Advanced device and lead systems can be expected to further improve both patient survival and quality of life after implant. The economic impact of unrestrained proliferation in ICD therapy can be enormous; however, available cost-benefit analyses support judicious use of this therapy with comparable economic impact to other accepted cardiovascular therapies. Such prospective risk stratification becomes economically essential when considering expanding its application to asymptomatic or minimally symptomatic populations at potential risk for future cardiac arrest.

This article has been cited by other articles:

				E. F.D. Wever, R. N.W. Hauer, G. Schrijvers, F. J.L. van Capelle, J. G.P. Tijssen, H. J.G.M. Crijns, A. Algra, H. Ramanna, P. F.A. Bakker, and E. O. Robles de Medina Cost-effectiveness of Implantable Defibrillator as First-Choice Therapy Versus Electrophysiologically Guided, Tiered Strategy in Postinfarct Sudden Death Survivors : A Randomized Study Circulation, February 1, 1996; 93(3): 489 - 496. [Abstract] [Full Text]

				N. A. Omoigui, F. I. Marcus, J. W. Mason, E. A. Hahn, V. L. Hartz, and M. A. Hlatky Cost of Initial Therapy in the Electrophysiological Study Versus ECG Monitoring Trial (ESVEM) Circulation, February 15, 1995; 91(4): 1070 - 1076. [Abstract] [Full Text]

				D. M. Roden Risks and Benefits of Antiarrhythmic Therapy N. Engl. J. Med., September 22, 1994; 331(12): 785 - 791. [Full Text]